A Phase 1, Open-label Study of the absorption, metabolism, and excretion of a single oral dose of \[14C\]EDP-938 in healthy male subjects.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
8
\[14C\]EDP-938
Covance Clinical Research Unit
Madison, Wisconsin, United States
Cmax of EDP-938 in plasma
Time frame: Up to 11 days
AUC0-tlast of EDP-938 in plasma
Time frame: Up to 11 days
AUC-inf in plasma
Time frame: Up to 11 days
Amount excreted in urine (Aeu)
Time frame: Up to 11 days
Amount excreted in feces (Aef)
Time frame: Up to 11 days
Cmax of EDP-938 metabolites in plasma
Time frame: Up to 11 days
Safety measured by occurrence of adverse events
Time frame: Up to 11 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.